Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Zentalis Pharmaceuticals Llc stock (ZNTL)

Buy Zentalis Pharmaceuticals Llc stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Zentalis Pharmaceuticals Llc is a biotechnology business based in the US. Zentalis Pharmaceuticals Llc shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. Zentalis Pharmaceuticals Llc employs 124 staff and has a trailing 12-month revenue of around $40.6 million.

Our top picks for where to buy Zentalis Pharmaceuticals Llc stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Zentalis Pharmaceuticals Llc stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ZNTL. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Zentalis Pharmaceuticals Llc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Not rated yet
OPTO
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
★★★★★
Stocks, ETFs, Cryptocurrency
$0
$0
4.5%
N/A
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Zentalis Pharmaceuticals Llc stock price (NASDAQ: ZNTL)

Use our graph to track the performance of ZNTL stocks over time.

Zentalis Pharmaceuticals Llc shares at a glance

Information last updated 2024-07-14.
Latest market close$3.95
52-week range$3.27 - $29.03
50-day moving average $8.88
200-day moving average $12.89
Wall St. target price$10.70
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.26

Is it a good time to buy Zentalis Pharmaceuticals Llc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zentalis Pharmaceuticals Llc price performance over time

Historical closes compared with the close of $3.95 from 2024-07-18

1 week (2024-07-12) -0.50%
1 month (2024-06-18) -4.59%
3 months (2024-04-19) -69.52%
6 months (2024-01-19) -69.36%
1 year (2023-07-19) -85.03%
2 years (2022-07-19) -86.87%
3 years (2021-07-19) 48.21
5 years (2019-07-15) N/A

Zentalis Pharmaceuticals Llc financials

Revenue TTM $40.6 million
Gross profit TTM $0
Return on assets TTM -24.93%
Return on equity TTM -51.87%
Profit margin 0%
Book value $6.46
Market Capitalization $281.9 million

TTM: trailing 12 months

Zentalis Pharmaceuticals Llc share dividends

We're not expecting Zentalis Pharmaceuticals Llc to pay a dividend over the next 12 months.

Zentalis Pharmaceuticals Llc share price volatility

Over the last 12 months, Zentalis Pharmaceuticals Llc's shares have ranged in value from as little as $3.27 up to $29.03. A popular way to gauge a stock's volatility is its "beta".

ZNTL.US volatility(beta: 1.71)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zentalis Pharmaceuticals Llc's is 1.705. This would suggest that Zentalis Pharmaceuticals Llc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Zentalis Pharmaceuticals Llc overview

Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc. ; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc.

Frequently asked questions

What percentage of Zentalis Pharmaceuticals Llc is owned by insiders or institutions?
Currently 3.989% of Zentalis Pharmaceuticals Llc shares are held by insiders and 120.85% by institutions.
How many people work for Zentalis Pharmaceuticals Llc?
Latest data suggests 124 work at Zentalis Pharmaceuticals Llc.
When does the fiscal year end for Zentalis Pharmaceuticals Llc?
Zentalis Pharmaceuticals Llc's fiscal year ends in December.
Where is Zentalis Pharmaceuticals Llc based?
Zentalis Pharmaceuticals Llc's address is: 1359 Broadway, New York, NY, United States, 10018
What is Zentalis Pharmaceuticals Llc's ISIN number?
Zentalis Pharmaceuticals Llc's international securities identification number is: US98943L1070
What is Zentalis Pharmaceuticals Llc's CUSIP number?
Zentalis Pharmaceuticals Llc's Committee on Uniform Securities Identification Procedures number is: 98943L107

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site